Menu
Search
|

Menu

Close
X

Bio Path Holdings Inc BPTH.OQ (NASDAQ Stock Exchange Capital Market)

1.64 USD
-0.03 (-1.80%)
As of 1:41 AM IST
chart
Previous Close 1.67
Open 1.68
Volume 7,059
3m Avg Volume 15,704
Today’s High 1.68
Today’s Low 1.55
52 Week High 10.10
52 Week Low 1.53
Shares Outstanding (mil) 100.06
Market Capitalization (mil) 38.52
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.595
FY16
-0.732
FY15
-0.609
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2,963.23
5.77
Price to Book (MRQ)
vs sector
4.35
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-70.12
14.43
Return on Equity (TTM)
vs sector
-83.80
16.13

EXECUTIVE LEADERSHIP

Peter Nielsen
Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Since
Salary: $400,000.00
Bonus: $75,000.00
Ulrich Mueller
Secretary, Since 2017
Salary: $285,000.00
Bonus: $42,394.00
Douglas Morris
Director, Since 2014
Salary: $40,000.00
Bonus: $12,000.00
Paul Aubert
Independent Director, Since 2018
Salary: --
Bonus: --
Heath Cleaver
Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4710 Bellaire Blvd Ste 210
BELLAIRE   TX   77401-4505

Phone: +1832.7421357

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

SPONSORED STORIES